

Coherus BioSciences Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 10-Nov-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

 Phase 3 Clinical..... 11

 Phase 1 Clinical..... 24

[Return to Table of Contents](#)

Coherus BioSciences Inc

COMPANY OVERVIEW

Company Name	Coherus BioSciences Inc
Parent Company Name	Coherus BioSciences Inc
Website	http://www.coherus.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	5
Number of Patents as Owner	9
Number of Patents as Third Party	0
Number of Deals	7
Key Indications	Rheumatoid arthritis, Psoriasis, Inflammatory disease, Febrile neutropenia, Ankylosing spondylitis, Psoriatic arthritis, Asthma, Atopic dermatitis, Cachexia, Chronic obstructive pulmonary disease, Crohns disease, Hepatitis C virus infection
Key Target-based Actions	TNF alpha ligand inhibitor, TNF antagonist, Type II TNF receptor modulator, B-lymphocyte antigen CD20 inhibitor, GCSF ligand, GCSF receptor agonist
Key Technologies	Biological therapeutic, Biosimilar product, Protein recombinant, Parenteral formulation unspecified, Subcutaneous formulation, Protein fusion, Liquid formulation, Monoclonal antibody human, Chimeric monoclonal antibody, Infusion, Intravenous formulation, PEGylated formulation, Systemic formulation unspecified

COMPANY PROFILE

SUMMARY

Coherus BioSciences was incorporated in Delaware in September 2010 under the name BioGenerics Inc and subsequently changed its name to Coherus BioSciences Inc in April 2012. It is a biopharmaceutical company specializing in biosimilars in the field of oncology and inflammation.

COMPANY LOCATION

Coherus is based in San Francisco, CA.

FINANCIAL

In March 2015, the company announced an underwritten public offering of \$100 million of common stock shares; underwriters were to be granted a 30-day option to purchase a further \$15 million of shares. Later that month, Coherus priced the underwritten public offering of 4,137,931 shares of its common stock at a price of \$29.00 per share. The underwriters were granted a 30-day option to purchase up to an additional 620,689 shares of common stock at the public offering price. The offering was expected to close on or about April 07, 2015.

In November 2014, the company priced its IPO of 6,296,300 shares of its common stock at \$13.50 per share, trading under ticker symbol 'CHRS', and granted the underwriters a 30-day option to purchase up to 944,445 additional common shares at the offering price. At that time, the offering was expected to close on November 12, 2014. In November 2014, the company closed the IPO of 6,803,702 of its common stock shares and included a purchase of 507,402 shares of the company's common stock by the underwriters with an option to purchase additional shares. At that time, the company expected the net proceeds to be approximately \$81.5 million.

In May 2014, the company raised \$55 million through a series C financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Unidentified indication	0	4	4
Inflammatory disease	2	0	2
Dermatological disease	2	0	2
Hematological disease	1	1	2
Immune disorder	2	0	2
Musculoskeletal disease	2	0	2
Neoplasm	0	1	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
No Development Reported	5
Phase 1 Clinical	1
Phase 3 Clinical	2

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	2	0	0	0	2
Drug - Manufacturing/Supply	0	0	5	0	5

[Return to Table of Contents](#)

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Immune disorder	4	4
Dermatological disease	3	3
Musculoskeletal disease	2	2
Inflammatory disease	2	2

Trials by Phase

Phase	Ongoing	All
Phase 3	4	4
Phase 1	1	3
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Immune disorder	4	0	4
Musculoskeletal disease	3	0	3
Neoplasm	1	0	1
Neurological disease	1	0	1
Nutritional disorder	2	0	2
Respiratory disease	3	0	3
Infectious disease	2	0	2
Cardiovascular disease	1	0	1
Gastrointestinal disease	3	0	3
Genitourinary disease	2	0	2

[Return to Table of Contents](#)



Hematological disease	1	0	1
Degeneration	1	0	1
Dermatological disease	4	0	4
Gynecology and obstetrics	1	0	1
Inflammatory disease	4	0	4

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta

etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta SNAPSHOT

Drug Name	etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta
Key Synonyms	etanercept
Originator Company	Coherus BioSciences Inc
Active Companies	Baxalta Inc;Coherus BioSciences Inc;Daiichi Sankyo Co Ltd
Inactive Companies	Baxter International Inc
Highest Status	Phase 3 Clinical
Active Indications	Inflammatory disease;Psoriasis;Rheumatoid arthritis
Target-based Actions	TNF alpha ligand inhibitor;TNF antagonist;Type II TNF receptor modulator
Other Actions	Anti-inflammatory;TNF binding agent
Technologies	Biological therapeutic;Biosimilar product;Liquid formulation;Protein fusion;Subcutaneous formulation
Last Change Date	28-Aug-2015

etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta DEVELOPMENT PROFILE

SUMMARY

Coherus BioSciences, in collaboration with licensees Daiichi Sankyo and Baxalta, a spin-out of Baxter, is developing BAX-2200 (CHS-0214), a biosimilar of etanercept, a fusion protein comprising the extracellular domain of human p75 TNF receptor linked to the Fc portion of human IgG1, which acts as a TNF alpha inhibitor, for the potential treatment of inflammatory conditions including rheumatoid arthritis (RA) and psoriasis ,,. In June 2014, a phase III study for rheumatoid arthritis was initiated. In July 2014, a phase III study for psoriasis was initiated ; in August 2014, the trial was initiated in Japan. In October 2013, data were reported from a pivotal confirmatory clinical trial in healthy subjects. In July 2015, BAX-2200 was listed as being in phase III development for psoriasis and RA on Baxalta's pipeline.

etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Baxalta Inc	Psoriasis	Australia	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Psoriasis	Canada	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Psoriasis	Chile	Phase 3 Clinical	01-Jul-2015

[Return to Table of Contents](#)

Company	Indication	Country	Development Status	Date
Baxalta Inc	Psoriasis	Europe	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Psoriasis	Germany	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Psoriasis	Israel	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Psoriasis	South Africa	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Psoriasis	US	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Rheumatoid arthritis	Argentina	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Rheumatoid arthritis	Europe	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Rheumatoid arthritis	Israel	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Rheumatoid arthritis	Japan	Phase 3 Clinical	01-Jul-2015
Baxalta Inc	Rheumatoid arthritis	US	Phase 3 Clinical	01-Jul-2015
Coherus BioSciences Inc	Psoriasis	Australia	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	Canada	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	Chile	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	Europe	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	Israel	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	South Africa	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Psoriasis	US	Phase 3 Clinical	16-Jul-2014
Coherus BioSciences Inc	Rheumatoid arthritis	Argentina	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Rheumatoid arthritis	Europe	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Rheumatoid arthritis	Israel	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Rheumatoid arthritis	Japan	Phase 3 Clinical	25-Sep-2014
Coherus BioSciences Inc	Rheumatoid arthritis	South Africa	Phase 3 Clinical	16-Apr-2015
Coherus BioSciences Inc	Rheumatoid arthritis	US	Phase 3 Clinical	23-Jun-2014
Daiichi Sankyo Co Ltd	Inflammatory disease	Japan	Phase 3 Clinical	18-Aug-2014
Daiichi Sankyo Co Ltd	Psoriasis	Australia	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Psoriasis	Canada	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Psoriasis	Chile	Phase 3 Clinical	25-Sep-2014

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Daiichi Sankyo Co Ltd	Psoriasis	Europe	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Psoriasis	Israel	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Psoriasis	South Africa	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	Argentina	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	Europe	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	Israel	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	Japan	Phase 3 Clinical	25-Sep-2014
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	South Africa	Phase 3 Clinical	16-Apr-2015
Daiichi Sankyo Co Ltd	Rheumatoid arthritis	US	Phase 3 Clinical	23-Jun-2014
Baxalta Inc	Inflammatory disease	Europe	Clinical	01-Jul-2015
Coherus BioSciences Inc	Inflammatory disease	US	Clinical	28-Oct-2013
Baxalta Inc	Inflammatory disease	Brazil	Discovery	01-Jul-2015
Baxalta Inc	Inflammatory disease	Canada	Discovery	01-Jul-2015
Daiichi Sankyo Co Ltd	Inflammatory disease	South Korea	Discovery	07-May-2012
Daiichi Sankyo Co Ltd	Inflammatory disease	Taiwan	Discovery	07-May-2012

etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta DRUG NAMES

Names	Type
BAX-2200	Research Code
CHS-0214	Research Code
etanercept	INN, BANN, USAN
etanercept biosimilar, Coherus BioSciences/ Daiichi Sankyo/ Baxter	
etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta	

etanercept biosimilar, Coherus BioSciences/Daiichi Sankyo/Baxalta CLINICAL TRIALS

Trials by Phase and Condition Studied

[Return to Table of Contents](#)



Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Rheumatoid arthritis											
0	0	2	2	0	0	0	0	0	0	2	2
Psoriasis											
0	0	2	2	0	0	0	0	0	0	2	2

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	3	3	0	0	0	1	0	0	3	4

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Coherus BioSciences Inc	2	0	3	0	5
Daiichi Sankyo Co Ltd	0	0	1	0	1
Dr Rentschler Holding GmbH & Co KG	1	0	0	0	1
Baxter International Inc	0	0	1	0	1
Cook Group Inc	1	0	0	0	1
Catalent Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Manufacturing/Supply	3	0	3
Drug - Development/Commercialization License	2	0	2

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Coherus BioSciences Inc	3	0	3

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1
Process	1
General interest	1

[Return to Table of Contents](#)

adalimumab biosimilar, Coherus

adalimumab biosimilar, Coherus SNAPSHOT

Drug Name	adalimumab biosimilar, Coherus
Key Synonyms	adalimumab
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Psoriasis;Rheumatoid arthritis
Target-based Actions	TNF alpha ligand inhibitor
Other Actions	Anti-inflammatory;TNF binding agent
Technologies	Biological therapeutic;Biosimilar product;Monoclonal antibody human;Parenteral formulation unspecified;Protein recombinant;Systemic formulation unspecified
Last Change Date	04-Sep-2015

adalimumab biosimilar, Coherus DEVELOPMENT PROFILE

SUMMARY

Coherus BioSciences is developing CHS-1420, a humanized biosimilar version of adalimumab (Humira), for the potential treatment of rheumatoid arthritis (RA) and psoriasis . In September 2015, a phase III trial was initiated in psoriasis . In August 2015, a BLA was expected to be filed in the US in the second half of 2016. In August 2014, the company planned for seeking to outlicense the drug outside the US.

adalimumab biosimilar, Coherus DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Coherus BioSciences Inc	Psoriasis	US	Phase 3 Clinical	03-Sep-2015
Coherus BioSciences Inc	Rheumatoid arthritis	US	Phase 1 Clinical	14-Aug-2014

[Return to Table of Contents](#)

adalimumab biosimilar, Coherus DRUG NAMES

Names	Type
CHS-1420	Research Code
adalimumab	INN, USAN
adalimumab biosimilar, Coherus	

adalimumab biosimilar, Coherus CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Psoriasis											
0	0	1	1	0	0	0	0	0	0	1	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	1	0	0	0	0	0	1	1	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Coherus BioSciences Inc	0	0	1	0	1
Cook Group Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Manufacturing/Supply	1	0	1

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Payne and Payne Dentistry	0	1	1
Florida Gulf Coast Center for Oral and Maxillofacial surgery	0	1	1
Coherus BioSciences Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1

[Return to Table of Contents](#)

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences SNAPSHOT

Drug Name	pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences
Key Synonyms	pegfilgrastim
Originator Company	Coherus BioSciences Inc
Active Companies	Coherus BioSciences Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Febrile neutropenia
Target-based Actions	GCSF receptor agonist;GCSF ligand
Other Actions	Hematopoietic stimulant;Neutrophil stimulator
Technologies	Biological therapeutic;Biosimilar product;PEGylated formulation;Protein recombinant;Subcutaneous formulation
Last Change Date	02-Oct-2015

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences DEVELOPMENT PROFILE

SUMMARY

Coherus BioSciences is developing CHS-1701, a biosimilar version of the PEGylated granulocyte colony stimulating factor ligand pegfilgrastim, for the potential sc treatment of febrile neutropenia in breast cancer patients. In November 2012, phase I trial was initiated. In March 2013, the trial was completed. In March 2015, a BLA-enabling pivotal study was initiated, on receiving feedback from the US FDA. In September 2014, the company planned for seeking to outlicense the drug outside the US.

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Coherus BioSciences Inc	Febrile neutropenia	US	Phase 1 Clinical	30-Nov-2012

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences DRUG NAMES

Names	Type
CHS-1701	Research Code
pegfilgrastim	INN, BANN, USAN
pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences	

[Return to Table of Contents](#)

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences CLINICAL TRIALS


Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	1	2	0	0	1	2

pegfilgrastim biosimilar (febrile neutropenia), Coherus BioSciences DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Coherus BioSciences Inc	0	0	2	0	2
JSR Corp	1	0	0	0	1
Cytovance Biologics LLC	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Manufacturing/Supply	2	0	2

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

